ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the expected results of their Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to the positive statements made by the defendants [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].